ENVB

ENVB

USD

Enveric Biosciences Inc. Common Stock

$5.700-0.400 (-6.557%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$6.100

高値

$6.645

安値

$5.520

出来高

0.25M

企業ファンダメンタルズ

時価総額

3.0M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.07M

取引所

NCM

通貨

USD

52週レンジ

安値 $5.52現在値 $5.700高値 $1444.5

関連ニュース

BusinessWire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic

もっと見る
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
BusinessWire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that

もっと見る
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
BusinessWire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or

もっと見る
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
BusinessWire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or

もっと見る
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications